GlassScriptPhysician profile
Alberto Mendez
NPI 1679503452
$1,788.40
in general payments reported to CMS, 2019-2025
23 companies · $45.36 in 2025
The $45.36 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $878 · 2021: $11.33 · 2022: $40.56 · 2023: $36.60 · 2025: $45.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.20 | 2019-2022 | |
| Medtronic Minimed, INC. | $249.34 | 2019-2020 | |
| Amgen INC. | $212.54 | 2019-2020 | |
| Abbvie INC. | $193.81 | 2019-2020 | |
| Lilly USA, LLC | $170.24 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $107.53 | 2019-2020 | |
| Insulet Corporation | $57.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.50 | 2020 | |
| Abbott Laboratories | $45.60 | 2019-2020 | |
| Ibsa Pharma INC. | $37.27 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.08 | 2020 | |
| Chiesi USA, INC. | $24.68 | 2025 | Elfabrio |
| Mannkind Corporation | $20.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.68 | 2025 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $19.89 | 2023 | Tymlos |
| Tandem Diabetes Care, INC. | $18.69 | 2020 | |
| Companion Medical, INC. | $17.78 | 2020 | |
| Allergan, INC. | $17.73 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.47 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.71 | 2023 | Adthyza |
| Acerus Pharmaceuticals Corporation | $13.79 | 2020 | |
| Shire North American Group INC | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.